Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor–Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis
Year: 2017
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Background: In sub-Saharan Africa, 25.5 million people are living with human immunodeficiency virus (HIV), representing 70% of the global total. The need for second-line antiretroviral therapy (ART) is projected to increase in the next decade in keeping with the expansion of treatment provision. Outcome data are required to inform policy. Methods: We performed a systematic review and meta-analysis of studies reporting the virological outcomes of protease inhibitor (PI)-based second-line ART in sub-Saharan Africa. The primary outcome was virological suppression (HIV-1 RNA <400 copies/mL) after 48 and 96 weeks of treatment. The secondary outcome was the proportion of patients with PI resistance. Pooled aggregate data were analyzed using a DerSimonian-Laird random effects model. Results: By intention-to-treat analysis, virological suppression occurred in 69.3% (95% confidence interval [CI], 58.2%-79.3%) of patients at week 48 (4558 participants, 14 studies), and in 61.5% (95% CI, 47.2%-74.9%) at week 96 (2145 participants, 8 studies). Preexisting resistance to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) increased the likelihood of virological suppression. Major protease resistance mutations occurred in a median of 17% (interquartile range, 0-25%) of the virological failure population and increased with duration of second-line ART. Conclusions: One-third of patients receiving PI-based second-line ART with continued NRTI use in sub-Saharan Africa did not achieve virological suppression, although among viremic patients, protease resistance was infrequent. Significant challenges remain in implementation of viral load monitoring. Optimizing definitions and strategies for management of second-line ART failure is a research priority. Prospero Registration: CRD42016048985.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/cix1108
Authors: Alexander J Stockdale, Matthew J Saunders, Mark A Boyd, Laura J Bonnett, Victoria Johnston, Gilles Wandeler, Annelot F Schoffelen, Laura Ciaffi, Kristen Stafford, Ann C Collier, Nicholas I Paton, Anna Maria Geretti
Institutions: University of Liverpool, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Imperial College London, Wellcome Trust, Lyell McEwin Hospital, UNSW Sydney, Kirby Institute, The University of Adelaide, London School of Hygiene & Tropical Medicine, University of Bern, University Hospital of Bern, University Medical Center Utrecht, Inserm, Université de Montpellier, Institut de Recherche pour le Développement, University of Maryland, Baltimore, University of Washington, National University of Singapore
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,359
Awards: Community randomised evaluation of socioeconomic intervention to prevent TB, AIDS Clinical Trials Group Network, Statistical and Data Management Center for the AIDS Clinical Trials Group, Preventing TB in people at high-risk, G7738973185, Hepatitis B in Malawi: Epidemiology and determinants of fibrosis and virological expression, G9000039438, G9000332881, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, University of Washington/Fred Hutch Center for AIDS Research, Statistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), Seattle Clinical Trials Unit
OpenAlex ID: W2780240470
